The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial

Overview

Journal Int J Prev Med

Date 2016 Apr 15

PMID 27076897

Citations 36

Authors

Atefe Asgharian

Gholamreza Askari

Ahmad Esmailzade

Awat Feizi

Vida Mohammadi

Affiliations

Soon will be listed here.

Abstract

Background: Regarding to the growing prevalence of nonalcoholic fatty liver disease (NAFLD), concentrating on various strategies to its prevention and management seems necessary. The aim of this study was to determine the effects of symbiotic on C-reactive protein (CRP), liver enzymes, and ultrasound findings in patients with NAFLD.

Methods: Eighty NAFLD patients were enrolled in this randomized, double-blind, placebo-controlled clinical trial. Participants received symbiotic in form of a 500 mg capsule (containing seven species of probiotic bacteria and fructooligosaccharides) or a placebo capsule daily for 8 weeks. Ultrasound grading, CRP, and liver enzymes were evaluated at the baseline and the end of the study.

Results: In the symbiotic group, ultrasound grade decreased significantly compared to baseline (P < 0.005) but symbiotic supplementation was not associated with changes in alanine aminotransferase (ALT) and aspartate transaminase (AST) levels. In the placebo group, there was no significant change in steatosis grade whereas ALT and AST levels were significantly increased (P = 0.002, P = 0.02, respectively). CRP values remained static in either group.

Conclusions: Symbiotic supplementation improved steatosis in NAFLD patients and might be useful in the management of NAFLD or protective against its progression.

Citing Articles

Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Rajewski P, Ciescinski J, Rajewski P, Suwala S, Rajewska A, Potasz M Biomedicines. 2025; 13(1).

PMID: 39857800 PMC: 11760440. DOI: 10.3390/biomedicines13010217.

The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.

Song Y, Liu S, Zhang L, Zhao W, Qin Y, Liu M Front Nutr. 2025; 11():1470185.

PMID: 39834471 PMC: 11743284. DOI: 10.3389/fnut.2024.1470185.

Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.

Marroncini G, Naldi L, Martinelli S, Amedei A Biomedicines. 2024; 12(7).

PMID: 39061972 PMC: 11273695. DOI: 10.3390/biomedicines12071398.

Gut-liver axis: Potential mechanisms of action of food-derived extracellular vesicles.

Zhang S, Wang Q, Tan D, Sikka V, Ng C, Xian Y J Extracell Vesicles. 2024; 13(6):e12466.

PMID: 38887165 PMC: 11183959. DOI: 10.1002/jev2.12466.

Gut microbiota in MAFLD: therapeutic and diagnostic implications.

Alghamdi W, Mosli M, Alqahtani S Ther Adv Endocrinol Metab. 2024; 15:20420188241242937.

PMID: 38628492 PMC: 11020731. DOI: 10.1177/20420188241242937.

References

Kekkonen R, Sysi-Aho M, Seppanen-Laakso T, Julkunen I, Vapaatalo H, Oresic M . Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol. 2008; 14(20):3188-94. PMC: 2712851. DOI: 10.3748/wjg.14.3188. View

Wong V, Won G, Chim A, Chu W, Yeung D, Li K . Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013; 12(2):256-62. View

Osman N, Adawi D, Ahrne S, Jeppsson B, Molin G . Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig Liver Dis. 2007; 39(9):849-56. DOI: 10.1016/j.dld.2007.06.001. View

Aller R, de Luis D, Izaola O, Conde R, Gonzalez Sagrado M, Primo D . Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9):1090-5. View

Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M . Gut-liver axis: a new point of attack to treat chronic liver damage?. Am J Gastroenterol. 2002; 97(8):2144-6. DOI: 10.1111/j.1572-0241.2002.05942.x. View

Bellentani S, Saccoccio G, Masutti F, Croce L, Brandi G, Sasso F . Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132(2):112-7. DOI: 10.7326/0003-4819-132-2-200001180-00004. View

Sherman P, Johnson-Henry K, Yeung H, Ngo P, Goulet J, Tompkins T . Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005; 73(8):5183-8. PMC: 1201237. DOI: 10.1128/IAI.73.8.5183-5188.2005. View

Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R . Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2011; 57(2):545-53. DOI: 10.1007/s10620-011-1887-4. View

Clark J . Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006; 40 Suppl 1:S39-43. DOI: 10.1097/01.mcg.0000168641.31321.fa. View

10.

Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A . Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18):2867-71. PMC: 2710729. DOI: 10.3748/wjg.14.2867. View

11.

Clausen M, Mortensen P . Lactulose, disaccharides and colonic flora. Clinical consequences. Drugs. 1997; 53(6):930-42. PMC: 7100287. DOI: 10.2165/00003495-199753060-00003. View

12.

Carr F, Chill D, Maida N . The lactic acid bacteria: a literature survey. Crit Rev Microbiol. 2003; 28(4):281-370. DOI: 10.1080/1040-840291046759. View

13.

Roselli M, Finamore A, Britti M, Mengheri E . Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr. 2006; 95(6):1177-84. DOI: 10.1079/bjn20051681. View

14.

Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R . Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49(6):1877-87. DOI: 10.1002/hep.22848. View

15.

Alavian S, Mohammad-Alizadeh A, Esna-Ashari F, Ardalan G, Hajarizadeh B . Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int. 2008; 29(2):159-63. DOI: 10.1111/j.1478-3231.2008.01790.x. View

16.

Ma Y, Li L, Yu C, Shen Z, Chen L, Li Y . Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013; 19(40):6911-8. PMC: 3812493. DOI: 10.3748/wjg.v19.i40.6911. View

17.

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

18.

Adams L, Angulo P . Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 2006; 82(967):315-22. PMC: 2563793. DOI: 10.1136/pgmj.2005.042200. View

19.

Rodriguez-Hernandez H, Cervantes-Huerta M, Rodriguez-Moran M, Guerrero-Romero F . Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Ann Hepatol. 2011; 10(4):486-92. View

20.

Festi D, Schiumerini R, Eusebi L, Marasco G, Taddia M, Colecchia A . Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014; 20(43):16079-94. PMC: 4239493. DOI: 10.3748/wjg.v20.i43.16079. View